Clinical trial

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT03480646

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-11-15

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2017-11-15Date precision: day

Registry last updated2025-10-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)unresolved

Interventions

CPI-1205DRUG

CobicistatDRUG · verified · RxNorm: cobicistat

EnzalutamideDRUG · verified · RxNorm: enzalutamide

AbirateroneDRUG · verified · RxNorm: abiraterone

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Constellation Pharmaceuticalslead sponsor

Mapped research locations

New YorkNew York, United States2 ChicagoIllinois, United States2 BaltimoreMaryland, United States2 AuroraColorado, United States2 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 MiamiFlorida, United States1 ColumbusOhio, United States1 TampaFlorida, United States1 DurhamNorth Carolina, United States1 IndianapolisIndiana, United States1 JacksonvilleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03480646 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.